First-in-human study of CDNF in patients with Parkinson's disease

Trial Profile

First-in-human study of CDNF in patients with Parkinson's disease

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs CDNF (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; First in man
  • Sponsors Herantis Pharma
  • Most Recent Events

    • 27 Sep 2017 According to a Herantis Pharma media release, first study site, Karolinska University Hospital in Stockholm, Sweden, has already consented the first patient in the study. Two further study sites, Helsinki University Hospital in Finland and Lund University Hospital in Sweden, are planned to initiate patient recruitment as soon as the required safety data cumulate from the first study site.
    • 27 Sep 2017 Status changed from planning to recruiting, according to a Herantis Pharma media release.
    • 29 Aug 2017 According to a Herantis Pharma media release, begning of patient recuitment is expected at in Q3/2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top